TrialDrug design, development and therapy2026
Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.
Lijun Ye et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.